LEIDOS BIOMEDICAL RESEARCH INC - IND-DIRECTED DEVELOPMENT OF ANTIVIRAL THERAPIES TO COMBAT DISEASES OF PANDEMIC POTENTIAL

PIID: 75N91022F00010

Signed Date: Dec 1, 2025Effective Date: Jul 27, 2022End Date: Closes in 317 days

Award $

$16.9M

Vendor

LEIDOS BIOMEDICAL RESEARCH INC

NAICS

541715

Signed Date

Dec 1, 2025

Key Details

Dollars Obligated

$16.9M

Base & All Options

$-1,843,960

Awarding Agency

Awarding Sub-Agency

National Institutes of Health

NAICS Code

Product Service Code

AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Extent Competed

FULL AND OPEN COMPETITION

Place of Performance

FREDERICK, MD, 217032817, CD-MD-06

IND-DIRECTED DEVELOPMENT OF ANTIVIRAL THERAPIES TO COMBAT DISEASES OF PANDEMIC POTENTIAL

On Dec 1, 2025, Department of Health and Human Services obligated $16,869,382 to LEIDOS BIOMEDICAL RESEARCH INC for ind-directed development of antiviral therapies to combat diseases of pandemic potential. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition. Performance is located in FREDERICK, MD. The contract is scheduled through Jul 26, 2027 — approximately 11 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.